IO Biotech announced that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company's investigational immune-modulating cancer vaccine, in combination with pembrolizumab in patients with BCG-unresponsive or intolerant, non-muscle invasive bladder cancer (NMIBC). This is one of five investigator-initiated trials IO Biotech is supporting to evaluate IO102-IO103 in combination with different checkpoint inhibitor-based regimens across a variety of cancer types.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 USD | -2.36% | -7.12% | -34.04% |
May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.04% | 83.67M | |
+52.53% | 63.85B | |
-2.41% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.34% | 26.52B | |
-21.55% | 18.69B | |
+2.83% | 12.73B | |
+22.08% | 12.11B | |
+27.67% | 12.07B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center